Myricetin

Myricetin

SCHEMBL4983336

O=c1c(O)c(-c2cc(O)c(O)c(O)c2)oc2cc(O)cc(O)c12.O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 12/20 0.72
MEN1 O00255 11/20 0.72
CYP3A4 P08684 11/20 0.72
KDM4E B2RXH2 10/20 0.72
MAPT P10636 10/20 0.72
FTO Q9C0B1 10/20 0.72
ABCB1 P08183 10/20 0.72
HSD17B10 Q99714 9/20 0.72
CYP2C9 P11712 9/20 0.72
ALOX15 P16050 8/20 0.72
ALDH1A1 P00352 8/20 0.72
HPGD P15428 8/20 0.72
CYP1A2 P05177 8/20 0.72
CYP1A1 P04798 8/20 0.72
CYP1B1 Q16678 8/20 0.72
XDH P47989 8/20 0.72
HIF1A Q16665 7/20 0.72
SLCO2B1 O94956 7/20 0.72
CYP2D6 P10635 7/20 0.72
CYP2C19 P33261 7/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Quercetin SCHEMBL8116614 0.92 MEN1 (0.77) KMT2AMEN1CYP3A4KDM4EMAPT
Kaempferol SCHEMBL5251789 0.90 MEN1 (0.75) KMT2AMEN1CYP3A4KDM4EMAPT
Myricetin SCHEMBL15609358 0.89 MEN1 (0.89) KMT2AMEN1CYP3A4KDM4EMAPT
Kaempferol SCHEMBL17732292 0.87 KMT2A (0.67) KMT2AMEN1CYP3A4KDM4EMAPT
Quercetin SCHEMBL2407213 0.87 MEN1 (0.81) KMT2AMEN1CYP3A4KDM4EMAPT
Myricetin SCHEMBL1545840 0.85 MEN1 (0.70) KMT2AMEN1CYP3A4KDM4EMAPT
Apigenin SCHEMBL29351464 0.85 KMT2A (1.00) KMT2AMEN1CYP3A4KDM4EMAPT
Apigenin SCHEMBL19428 0.85 KMT2A (1.00) KMT2AMEN1CYP3A4KDM4EMAPT
Apigenin SCHEMBL5083245 0.85 KMT2A (1.00) KMT2AMEN1CYP3A4KDM4EMAPT
Myricetin SCHEMBL3503992 0.85 MEN1 (1.00) KMT2AMEN1CYP3A4KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080069779-A1 Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof FOAMIX LTD. (IL) 2008-03-20 US claimed
US-10585370-B2 Charging member, process cartridge, and electrophotographic image forming apparatus CANON KABUSHIKI KAISHA (JP) 2020-03-10 US disclosed
US-20190033746-A1 CHARGING MEMBER, PROCESS CARTRIDGE, AND ELECTROPHOTOGRAPHIC IMAGE FORMING APPARATUS CANON KK (JP) 2019-01-31 US disclosed
US-20080069779-A1 Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof FOAMIX LTD. (IL) 2008-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080069779-A1 Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof PROC, VKORC1, TTPA KMT2A 4666/4885MEN1 2845/4885CYP3A4 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.